Alterity Therapeutics is a pioneering brand on a mission to revolutionize the future for individuals with neurodegenerative diseases. With a strong commitment to improving lives, Alterity Therapeutics aims to disrupt the current trajectory and offer an alternate, healthier life for those affected by these conditions. Established in 1997 as Prana Biotechnology, the company has a rich history and a global presence, with offices in Melbourne, Australia, and San Francisco, USA.

The brand is listed on both the Australian Securities Exchange (ASX: ATH) and the NASDAQ (NASDAQ: ATHE). Led by a team of experienced professionals, including CEO David Stamler, MD, and CFO Kathryn Andrews, B. Com, CPA, Alterity Therapeutics is dedicated to advancing the field of neurodegenerative disease treatment through their innovative pipeline and cutting-edge research.

The brand's nonclinical development is overseen by Vice President Margaret Bradbury, Ph. D. Backed by a diverse Board of Directors, including Chairman and Founder Geoffrey Kempler, B.

Sc., Grad. Dip. App.

Soc. Psych, Alterity Therapeutics has a strong strategic plan in place for the commercialization of their technology. Lawrence Gozlan, B.

Sc. (Hons), and Peter Marks, BEc LLB Grad. Dip.

Comm. Law MBA, alongside Brian Meltzer, B. Com., M Ec., provide invaluable expertise and guidance to propel the brand's success.

In conclusion, Alterity Therapeutics is committed to forging an alternate future, where individuals living with neurodegenerative diseases can experience improved quality of life. With their dedicated team and groundbreaking advancements, Alterity Therapeutics is a beacon of hope in the field of neurodegenerative disease treatment